Literature DB >> 20673996

Is cardiometabolic risk improved by weight-loss drugs?

Arne Astrup1.   

Abstract

Mesh:

Substances:

Year:  2010        PMID: 20673996     DOI: 10.1016/S0140-6736(10)60999-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  Comparative efficiency and safety of pharmacological approaches to the management of obesity.

Authors:  Vojtech Hainer
Journal:  Diabetes Care       Date:  2011-05       Impact factor: 19.112

2.  Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.

Authors:  A Astrup; R Carraro; N Finer; A Harper; M Kunesova; M E J Lean; L Niskanen; M F Rasmussen; A Rissanen; S Rössner; M J Savolainen; L Van Gaal
Journal:  Int J Obes (Lond)       Date:  2011-08-16       Impact factor: 5.095

Review 3.  Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date.

Authors:  Assumpta Caixàs; Lara Albert; Ismael Capel; Mercedes Rigla
Journal:  Drug Des Devel Ther       Date:  2014-09-18       Impact factor: 4.162

4.  Effect of soybean milk fermented with Lactobacillus plantarum HFY01 isolated from yak yogurt on weight loss and lipid reduction in mice with obesity induced by a high-fat diet.

Authors:  Chong Li; Huilin Liu; Jiao Yang; Jianfei Mu; Ranran Wang; Xin Zhao
Journal:  RSC Adv       Date:  2020-09-15       Impact factor: 4.036

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.